We have located links that may give you full text access.
Different causes of early and late-onset post transplant lymphoproliferative disorder in kidney transplantation patients after 2000.
Asian Journal of Surgery 2018 October 14
BACKGROUND: The purpose of this study was to analyze the link between PTLD incidence and its occurrence time in patients at a single center in comparable medical environments after 2000.
METHODS: Retrospectively, total 3305 kidney transplantation patients medical data were analyzed. Patients were divided into two groups based on the period from the day of kidney transplantation to the day of PTLD diagnosis. Early-onset was defined as PTLD development within two years after transplantation, whereas all other cases were categorized as late-onset PTLD.
RESULTS: In the early-onset group, young age (0-19 years) was confirmed as a risk factor for PTLD incidence (HR 1.49, p = 0.038). In the late-onset group, history of anti-rejection therapy was confirmed as a risk factor (HR 1.32, p = 0.031). Overall survival rates were not significantly different between the two groups (p = 0.556). Graft survival rates were also not different between the two groups (p = 0.549).
CONCLUSION: When patients with PTLD were classified into early-onset group and late-onset group at two years, overall survival and graft survival were comparable. And patients with early-onset PTLD are more likely to be associated with EBV, the late-onset patients are more likely to be immunosuppressed.
METHODS: Retrospectively, total 3305 kidney transplantation patients medical data were analyzed. Patients were divided into two groups based on the period from the day of kidney transplantation to the day of PTLD diagnosis. Early-onset was defined as PTLD development within two years after transplantation, whereas all other cases were categorized as late-onset PTLD.
RESULTS: In the early-onset group, young age (0-19 years) was confirmed as a risk factor for PTLD incidence (HR 1.49, p = 0.038). In the late-onset group, history of anti-rejection therapy was confirmed as a risk factor (HR 1.32, p = 0.031). Overall survival rates were not significantly different between the two groups (p = 0.556). Graft survival rates were also not different between the two groups (p = 0.549).
CONCLUSION: When patients with PTLD were classified into early-onset group and late-onset group at two years, overall survival and graft survival were comparable. And patients with early-onset PTLD are more likely to be associated with EBV, the late-onset patients are more likely to be immunosuppressed.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app